ArticleJournal of cosmetic dermatology2026
Efficacy of PicoSure Laser in Treating Lichen Planus Pigmentosus and Pigmentary Demarcation Lines in Patients With Skin of Color.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLichen Planus Pigmentosus (LPP) and Pigmentary Demarcation Lines (PDL) are common pigmentary disorders among individuals with skin of color (SoC), presenting challenges for treatment due to risks of side effects, such as post-inflammatory hyperpigmentation (PIH). PicoSure laser, a 755-nm picosecond laser, has shown promise in treating pigmentary conditions with minimal adverse effects.
aimsTo evaluate the safety and efficacy of PicoSure laser treatment in patients with LPP and PDL, focusing on pigmentation reduction, patient satisfaction, and adverse effects. PATIENTS/
methodsA prospective case series was conducted over 16 weeks, involving 10 patients (5 LPP, 5 PDL) with Fitzpatrick skin types III-V. Patients underwent PicoSure laser treatment using a 755-nm wavelength, with assessments based on pigmentation reduction, patient satisfaction (via a visual analogue scale), and adverse effects.
resultsAll patients demonstrated significant improvement in pigmentation. In LPP cases, 4 patients achieved > 90% improvement (Grade V), while 1 patient showed > 75% (Grade IV) improvement. PDL patients had > 75% (Grade IV) improvement in the majority of the cases. No significant adverse effects were reported, with minimal PIH observed. High patient satisfaction was reported across all cases.
conclusionsPicoSure laser offers a safe and effective treatment for LPP and PDL in patients with skin of color, providing significant pigmentation reduction with minimal risk of PIH. It serves as a promising treatment alternative to traditional lasers, with potential for broader application in this demographic. Further studies with larger sample sizes are warranted to confirm long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.